October 19, 2016 / 11:20 AM / a year ago

BRIEF-Lannett seeks to withdraw approval of abbreviated NDA for methylphenidate hydrochloride extended release tablets

Oct 19 (Reuters) - Lannett Company Inc :

* Lannett comments on FDA proposal regarding methylphenidate extended release tablets

* Lannett company - will seek to withdraw approval of co’s abbreviated new drug application for methylphenidate hydrochloride extended-release tablets

* Lannett company inc - “remain confident that our methylphenidate er products are safe and effective”

* Lannett company - has until Nov 17, 2016 to request hearing and until Dec 19, 2016 to submit all data, information and analyses upon which request for a hearing relies

* Lannett company inc - fda’s proposal includes an opportunity for lannett to request a hearing on the matter Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below